A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic
Details
Age
Adult
Locations
Memorial Hospital Central
Memorial Hospital North
Principal Investigator
Robert Hoyer
Study ID
Protocol Number: 22-2095
More information available at ClinicalTrials.gov: NCT05555732
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers